Androgen receptor
The androgen receptor (AR) is a ligand-activated nuclear receptor protein that mediates cellular responses to androgens by regulating androgen receptor signaling.
The androgen receptor (AR) is a ligand-activated nuclear receptor protein that mediates cellular responses to androgens by regulating androgen receptor signaling. It is a major determinant of prostate-cell biology and a central therapeutic target in prostate cancer, where androgen deprivation therapy and androgen receptor signaling inhibitors are used in hormone-sensitive and castration-resistant disease. Recent studies have examined AR expression as a prognostic or clinicopathological feature, the relationship between AR signaling and treatment timing in metastatic hormone-sensitive prostate cancer, and mechanisms that influence androgen sensitivity, including DPP4-associated restoration of AR signaling.
AR is also being investigated as a target for therapeutic degradation and as a tumor-intrinsic regulator of immune interactions. HSP70-mediated HEMTACs represent an approach to AR-directed degradation, while proteome-guided analyses of experimental AR degraders have explored widespread responses associated with the hepatotoxicity of phthalimide degraders. In prostate cancer, genome-wide CRISPR screening has positioned AR among factors involved in macrophage-mediated tumor-cell killing. Beyond prostate cancer, immunohistochemical studies are evaluating AR expression in endometrial carcinoma, extending investigation of this receptor to additional hormone-responsive malignancies.
Where the papers sit
9 papers from the last 6 months study androgen receptor directly · updated from PubMed 9 Nov 2026
Study type 0 clinical trials · 3 observational · 1 human data · 4 preclinical · 1 unclassified
Themes one subject · 1 new direction
Those 9 are all about one subject.
-
Androgen Signaling in Cancer
Androgen signaling research spans tumor biology, clinical management, and therapeutic targeting across prostate, breast, and endometrial cancers. AR expression is being linked to clinicopathology, androgen sensitivity, tumor growth, and macrophage-mediated killing. Degrader development, including HSP70-mediated HEMTACs, is expanding beyond conventional receptor blockade, while proteomic and genetic screens seek resistance mechanisms and toxicity safeguards. Clinical studies continue to refine treatment timing and bone protection in advanced prostate cancer.
Androgen receptor signaling is a tumor-intrinsic regulator of macrophage-mediated tumor-cell killing
The genome-wide CRISPR screen in human prostate cancer cells co-cultured with macrophages found that AR and NF-κB drive PRKCD expression required for macrophage-mediated killing, whereas androgen deprivation or AR inhibition made tumor cells resistant 42521833Jul. This places AR outside the set’s prevailing roles in tumor growth, treatment response, degradation, or prognostic assessment: rather than merely supporting cancer-cell proliferation or serving as a therapeutic target, AR signaling can promote innate immune eradication of tumor cells. Consequently, suppressing AR may alter the tumor’s susceptibility to macrophages in addition to its direct effects on tumor-cell signaling.
Papers
The 9 papers from the last 6 months that study androgen receptor directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Androgen Signaling in Cancer (9)
- A modular lentiviral system for multiplexed gene perturbation and functional analysis suggests interdependence of hormone receptors in breast cancer growth in vivo. Life science alliance · 5 Nov 2026 PMID 42988560
- Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity. Nature chemical biology · 9 Oct 2026 PMID 42855516
- Immunohistochemical evaluation of androgen receptor expression in endometrial carcinoma and its clinicopathological significance. Diagnostic pathology · 25 Sept 2026 PMID 42791571
- Association of time to upfront treatment initiation with outcomes in metastatic hormone-sensitive prostate cancer: a 4-month landmark analysis. World journal of urology · 25 Sept 2026 PMID 42789110
- Proteomic profiling reveals that DPP4 overexpression increases cell adhesion, inhibits cell migration, and restores androgen sensitivity in prostate cancer. Bioscience reports · 24 Aug 2026 PMID 42634954
- Prostatic Androgen Receptor Expression in Men with Prostate Cancer. The Nigerian postgraduate medical journal · 19 Aug 2026 PMID 42616976
- A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator. Oncogene · 28 Jul 2026 PMID 42521833
- Design, synthesis, and biological evaluation of HSP70-mediated HEMTACs as novel androgen receptor degraders. European journal of medicinal chemistry · 1 Jul 2026 PMID 42385348
- Bayesian re-analysis of ERA223 and PEACE-3 temporal dynamics and bone protection in radium-223-treated metastatic castration-resistant prostate cancer. Japanese journal of clinical oncology · 15 Jun 2026 PMID 42296139
By study type
Observational studies and case reports (3)
- Immunohistochemical evaluation of androgen receptor expression in endometrial carcinoma and its clinicopathological significance. Diagnostic pathology · 25 Sept 2026 PMID 42791571
- Association of time to upfront treatment initiation with outcomes in metastatic hormone-sensitive prostate cancer: a 4-month landmark analysis. World journal of urology · 25 Sept 2026 PMID 42789110
- Prostatic Androgen Receptor Expression in Men with Prostate Cancer. The Nigerian postgraduate medical journal · 19 Aug 2026 PMID 42616976
Human data, design not indexed (1)
- Bayesian re-analysis of ERA223 and PEACE-3 temporal dynamics and bone protection in radium-223-treated metastatic castration-resistant prostate cancer. Japanese journal of clinical oncology · 15 Jun 2026 PMID 42296139
Preclinical: animal, cell and lab studies (4)
- A modular lentiviral system for multiplexed gene perturbation and functional analysis suggests interdependence of hormone receptors in breast cancer growth in vivo. Life science alliance · 5 Nov 2026 PMID 42988560
- Proteomic profiling reveals that DPP4 overexpression increases cell adhesion, inhibits cell migration, and restores androgen sensitivity in prostate cancer. Bioscience reports · 24 Aug 2026 PMID 42634954
- A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator. Oncogene · 28 Jul 2026 PMID 42521833
- Design, synthesis, and biological evaluation of HSP70-mediated HEMTACs as novel androgen receptor degraders. European journal of medicinal chemistry · 1 Jul 2026 PMID 42385348
Unclassified: not yet indexed with MeSH (1)
- Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity. Nature chemical biology · 9 Oct 2026 PMID 42855516
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-11-06. Drafted by language models from published abstracts; not medical advice.